Papapetropoulos Spyros
SEC insider (Form 3/4/5 filer). CIK 0001832694. President and CEO at Neuphoria Therapeutics Inc. (NEUP) and 1 other issuer. 4 reported Form 4/5 transactions since Sep 2024; latest on Aug 27, 2025. Located in BURLINGTON, MA.
Companies Papapetropoulos Spyros has filed insider reports for
- Neuphoria Therapeutics Inc. (NEUP): Director, Officer, President and CEO
- Lipocine Inc. (LPCN): Director
Papapetropoulos Spyros
CIK: 0001832694
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Aug 27, 2025NEUP
Neuphoria Therapeutics Inc.
AwardDirectEmployee Stock Option (Right-to- Buy)
34.6K shares at avg. $8.27- - Jun 4, 2025LPCN
Lipocine Inc.
AwardDirectStock Option (Right to Buy)
1.8K shares at avg. $3.20- - Apr 16, 2025NEUP
Neuphoria Therapeutics Inc.
AwardDirectEmployee Stock Option (Right-to-Buy)
27K shares at avg. $5.16- - Apr 16, 2025NEUP
Neuphoria Therapeutics Inc.
AwardDirectEmployee Stock Option (Right-to-Buy)
270K shares at avg. $5.16-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 27, 2025 |  NEUP Neuphoria Therapeutics Inc. | Award Employee Stock Option (Right-to- Buy) | 34,559 | $8.27 | - | Direct |
| Jun 4, 2025 |  LPCN Lipocine Inc. | Award Stock Option (Right to Buy) | 1,764 | $3.20 | - | Direct |
| Apr 16, 2025 | NEUP Neuphoria Therapeutics Inc. | Award Employee Stock Option (Right-to-Buy) | 27,000 | $5.16 | - | Direct |
| Apr 16, 2025 | NEUP Neuphoria Therapeutics Inc. | Award Employee Stock Option (Right-to-Buy) | 270,000 | $5.16 | - | Direct |
1-4 of 4 transactions